Happy to share our clinical case “IMAGES IN HAEMATOLOGY” of @BrJHaem 🗞️
<< Primary bone lymphoma with cervical compression mimicking solitary osseous plasmacytoma>>
• Key point: bone lymphoma may have
a clinical presentation indistinguishable from that of solitary plasmacytoma or metastatic carcinoma, and clinicians should suspect it in cases of persistent axial bone pain even without B-type
symptoms.
@FabioTorressav@PaolaPizano@DraLPardoG#lymphoma#lymsm
Link: onlinelibrary.wiley.com/doi/…@DrAEvens
Adding CD28 costimulation to glofitamab without new safety signals is the encouraging part for me. Did the benefit stay mostly in follicular lymphoma, as in the ASH 2024 escalation data, or did the aggressive histologies catch up with longer follow-up?
🎙️ What to Expect in Multiple Myeloma at #ASH26?
Looking at the abstracts already available, one message is clear:
we are witnessing a fundamental transformation in how we treat myeloma.
We are moving beyond conventional combinations of:
• Proteasome inhibitors
• Immunomodulatory agents
• Monoclonal antibodies
Toward a landscape increasingly dominated by:
• T-cell redirection
• Multi-antigen targeting
• Highly personalized immunotherapy
The question is no longer just:
How deep a response can we achieve?
It is becoming:
How do we translate these remarkable responses into durable survival, while minimizing toxicity and preserving patients' quality of life?
In our new podcast, we highlight 5 major developments we believe deserve particular attention at #ASH26 in New Orleans.
🎧 Listen here:
on.soundcloud.com/PR2CKPiJ8h…#MultipleMyeloma@Mohty_EBMT
Great Job @OpenMedInsights@OpenMedicineHQ team!
An excellent resource for the medical community. Algorithms covering various specialties, ranging from basic to advanced topics. Highly recommended!!!
How to reduce the efficacy of cancer immunotherapy?
Alcohol intake, and a mechanism identified in the experimental model @scisignalscience.org/doi/10.1126/scis…
· Open Medicine Algorithm Spotlight ·
Hypernatremia Diagnostic Evaluation: Stepwise Clinical and Laboratory Approach (by @iamnephrologist)
@OpenMedicineHQ
Key points:
- Concordance among sodium, measured osmolality, glucose, and measurement method distinguishes true hypertonic hypernatremia from analytical or osmolar discordance.
- Neurologic findings reflect the severity and rapidity of hypertonicity, while hemodynamic and physical findings determine whether urgent volume resuscitation is required.
- Classification as hypovolemic, euvolemic, or hypervolemic is a standard organizing step that narrows the balance of total-body water and sodium.
** Hypovolemic hypernatremia reflects combined sodium and water loss with proportionally greater water loss; orthostasis, tachycardia, low venous pressure, and prerenal kidney injury are supportive.
** Euvolemic hypernatremia usually represents relatively pure water loss through renal or extrarenal routes without clinically apparent sodium depletion or overload.
** Volume overload accompanying hypernatremia should prompt evaluation for hypertonic sodium administration, ingestion, dialysis-related loading, or less commonly mineralocorticoid-mediated retention.
LIVING algorithm link: myopenmedicine.com/algorithm…#OpenMedicine#Nephrology#NephTwitter#KidneyDisease#NephPearls#InternalMedicine@OpenMedKate@scserendipity1
What to Expect in Multiple Myeloma at #ASH2026 ?
The #ASH26 Meeting in New Orleans promises to be particularly exciting for the multiple myeloma community. And looking at the abstracts already available, one message is becoming increasingly clear: we are witnessing a fundamental transformation in how we treat myeloma. We are moving beyond conventional combinations of proteasome inhibitors, immunomodulatory agents, and moAbs toward a therapeutic landscape increasingly dominated by T-cell redirection, multi-antigen targeting, and highly personalized immunotherapy. But the fundamental question is no longer simply: How deep a response can we achieve? It is becoming: How can we translate these remarkable responses into durable survival, while minimizing toxicity and preserving patients’ quality of life? In this @TheIACH podcast, we would like to highlight five major developments that we believe deserve particular attention at #ASH26.
soundcloud.com/cme-congresse…
Don't miss the next IACH Transplant Academy | Junior Club session!
Join @Yishan__Ye for an engaging case discussion:
A Hard Case of cGVHD
Monday, Nov 23
6 PM CET | 12 PM NY
🎟️ Save your spot – register for free:
us06web.zoom.us/webinar/regi…@Mohty_EBMT
Does CD5+ LBCL present unique questions for CNS prophylaxis?
Reply in @JCO_ASCO with @mattwilson2287 & @Dr_KatLewis#lymsm
Reply to: Unanswered Question Regarding CNS Prophylaxis in CD5-Positive Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO…
How does anti–PD-1 salvage perform outside clinical trials in R/R classical Hodgkin lymphoma?
A multicenter real-world study in Haematologica shows that while response rates varied, post-ASCT outcomes remain highly encouraging. doi.org/10.3324/haematol.202…#HemOnc#Lymphoma